Enallylpropymal (Narconumal) is a barbiturate derivative developed by Hoffman la Roche in the 1930s.[1] It has sedative and hypnotic effects and is considered to have a moderate abuse potential.[2]

References

  1. ^ US 2072829, Schnider O, "N-Methyl-5,5-allylisopropylbarbituric acid", issued 2 March 1937, assigned to Hoffmann-La Roche Inc. 
  2. ^ Eddy NB, Halbach H, Isbell H, Seevers MH (1965). "Drug dependence: its significance and characteristics". Bulletin of the World Health Organization. 32 (5): 721–33. PMC 2555251. PMID 5294186.